Aaliyah is a life sciences attorney and bioethicist. Her FDA regulatory consulting practice provides strategic guidance to pharmaceutical, medical device, and biotechnology companies developing, improving, and manufacturing pioneering products to meet the challenges of 21st century health care. She is also an experienced health care mediator and legal adviser for institutional, group practice, and individual health care providers.
She brings more than a decade of experience as a policy adviser and health care mediator for the U.S. Food and Drug Administration, U.S. Veterans Health Administration, and U.S. Department of Defense medical treatment facilities in Europe. She has focused on both the U.S. and international regulation of clinical trials, medical innovation, and adverse event reporting. Drawing upon her federal regulatory experience, she works with health care innovators to successfully traverse the ever-evolving health care regulatory environment from the research phase through post-market surveillance of their product. She assists clients in all industries to comply with state and federal labeling and advertising requirements.
In addition, she has significant experience leading health care alternative dispute resolution processes and has trained health care providers to have difficult conversations with patients about informed consent issues and unexpected clinical outcomes. Her alternative dispute resolution practice involves helping clients improve and manage communication and early resolution processes to identify and candidly discuss adverse health care incidents. She provides comprehensive legal services for Communication and Resolution Programs (CRPs). When correctly implemented, CRPs have improved quality of care, realized long-term cost savings, increased patient satisfaction, and reduced the prevalence of moral injury among health care providers.
Aaliyah recognizes the importance of strengthening crucial stakeholder relationships in health care and develops customized conflict mitigation strategies to achieve favorable results in both controversial clinical care cases and in regulatory meetings with federal and state agencies.
